Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Concurrent or Sequential Administration of Drugs for COVID-19 and Influenza

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1446-000
Expected finish date:

Question

  1. What is the clinical effectiveness and safety of concurrent administration of cilgavimab and tixagevimab, nirmatrelvir and ritonavir, and/or oseltamivir?
  2. What is the clinical effectiveness and safety of sequential administration of cilgavimab and tixagevimab, nirmatrelvir and ritonavir, and/or oseltamivir?
  3. What are the evidence-based guidelines regarding concurrent administration or sequential administration of cilgavimab and tixagevimab, nirmatrelvir and ritonavir, and/or oseltamivir?

Key Message

With the continued COVID-19 pandemic and the resurgence of seasonal influenza, there is the potential that some populations may need drugs for the prevention and/or treatment of COVID-19 and/or influenza at the same time (i.e., concurrent use) or close together (i.e., sequential use).

No evidence was identified regarding the clinical effectiveness, safety, or evidence-based guidelines for the concurrent or sequential use of cilgavimab and tixagevimab, nirmatrelvir and ritonavir, and/or oseltamivir that met the criteria for this review.

Files

Concurrent or Sequential Administration of Drugs for COVID-19 and Influenza View PDF
Last Updated : August 15, 2022